AU Patent

AU2012323856B2 — Methods for treating Vascular Leak Syndrome and cancer

Assigned to Eyepoint Pharmaceuticals Inc · Expires 2017-05-25 · 9y expired

What this patent protects

Disclosed are methods for treating Vascular Leak Syndrome and preventing cancer metastasis. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, sepsis, cancer or the presence of pathogens.

USPTO Abstract

Disclosed are methods for treating Vascular Leak Syndrome and preventing cancer metastasis. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, sepsis, cancer or the presence of pathogens.

Drugs covered by this patent

Patent Metadata

Patent number
AU2012323856B2
Jurisdiction
AU
Classification
—
Expires
2017-05-25
Drug substance claim
No
Drug product claim
No
Assignee
Eyepoint Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.